Loading clinical trials...
Loading clinical trials...
This is a multi-center, long-term safety and efficacy follow-up study for participants with cerebral adrenoleukodystrophy (CALD) who have received Lenti-D Drug Product (eli-cel) in a parent clinical s...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Genetix Biotherapeutics Inc.
NCT05819866 · Cerebral Adrenoleukodystrophy (cALD)
NCT01896102 · Cerebral Adrenoleukodystrophy (CALD)
NCT01043640 · Mucopolysaccharidosis, Hurler Syndrome, and more
Mattel Children's Hospital-UCLA
Los Angeles, California
Lucile Packard Children's Hospital - Stanford
Palo Alto, California
Boston Children's Hospital/Massachusetts General Hospital
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions